Lasofoxifene Reduces Risk of Breast Cancer, Fractures in Women With Osteoporosis
Doctor's Guide -- WASHINGTON, DC -- November 5, 2010 -- A study published in the Journal of the National Cancer Institute suggests that lasofoxifene (Fablyn) reduces the risk of breast cancer and fractures in postmenopausal women with osteoporosis.